tetano
Editor, Senior Moderator
Clin Infect Dis
. 2023 Sep 25;ciad469.
doi: 10.1093/cid/ciad469. Online ahead of print. Long-term Cardiovascular, Cerebrovascular, and Other Thrombotic Complications in Coronavirus Disease 2019 Survivors: A Retrospective Cohort Study
Jue Tao Lim[SUP] 1 2 [/SUP], Wee Liang En[SUP] 2 3 4 [/SUP], An Ting Tay[SUP] 5 [/SUP], Deanette Pang[SUP] 5 [/SUP], Calvin J Chiew[SUP] 2 5 [/SUP], Benjamin Ong[SUP] 5 6 [/SUP], David Chien Boon Lye[SUP] 1 2 6 7 [/SUP], Kelvin Bryan Tan[SUP] 1 5 8 [/SUP]
Affiliations
Background: Growing evidence suggests that some coronavirus disease 2019 (COVID-19) survivors experience a wide range of long-term postacute sequelae. We examined the postacute risk and burden of new-incident cardiovascular, cerebrovascular, and other thrombotic complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a highly vaccinated multiethnic Southeast Asian population, during Delta predominance.
Methods: This cohort study used national testing and healthcare claims databases in Singapore to build a cohort of individuals who had a positive SARS-CoV-2 test between 1 September and 30 November 2021 when Delta predominated community transmission. Concurrently, we constructed a test-negative control group by enrolling individuals between 13 April 2020 and 31 December 2022 with no evidence of SARS-CoV-2 infection. Participants in both groups were followed up for a median of 300 days. We estimated risks of new-incident cardiovascular, cerebrovascular, and other thrombotic complications using doubly robust competing-risks survival analysis. Risks were reported using 2 measures: hazard ratio (HR) and excess burden (EB) with 95% confidence intervals.
Results: We included 106 012 infected cases and 1 684 085 test-negative controls. Compared with the control group, individuals with COVID-19 exhibited increased risk (HR, 1.157 [1.069-1.252]) and excess burden (EB, 0.70 [.53-.88]) of new-incident cardiovascular and cerebrovascular complications. Risks decreased in a graded fashion for fully vaccinated (HR, 1.11 [1.02-1.22]) and boosted (HR, 1.10 [.92-1.32]) individuals. Conversely, risks and burdens of subsequent cardiovascular/cerebrovascular complications increased for hospitalized and severe COVID-19 cases (compared to nonhospitalized cases).
Conclusions: Increased risks and excess burdens of new-incident cardiovascular/cerebrovascular complications were reported among infected individuals; risks can be attenuated with vaccination and boosting.
Keywords: cardiovascular; cerebrovascular; complications; postacute sequelae of SARS-CoV-2 infection; thrombotic.
. 2023 Sep 25;ciad469.
doi: 10.1093/cid/ciad469. Online ahead of print. Long-term Cardiovascular, Cerebrovascular, and Other Thrombotic Complications in Coronavirus Disease 2019 Survivors: A Retrospective Cohort Study
Jue Tao Lim[SUP] 1 2 [/SUP], Wee Liang En[SUP] 2 3 4 [/SUP], An Ting Tay[SUP] 5 [/SUP], Deanette Pang[SUP] 5 [/SUP], Calvin J Chiew[SUP] 2 5 [/SUP], Benjamin Ong[SUP] 5 6 [/SUP], David Chien Boon Lye[SUP] 1 2 6 7 [/SUP], Kelvin Bryan Tan[SUP] 1 5 8 [/SUP]
Affiliations
- PMID: 37746872
- DOI: 10.1093/cid/ciad469
Background: Growing evidence suggests that some coronavirus disease 2019 (COVID-19) survivors experience a wide range of long-term postacute sequelae. We examined the postacute risk and burden of new-incident cardiovascular, cerebrovascular, and other thrombotic complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a highly vaccinated multiethnic Southeast Asian population, during Delta predominance.
Methods: This cohort study used national testing and healthcare claims databases in Singapore to build a cohort of individuals who had a positive SARS-CoV-2 test between 1 September and 30 November 2021 when Delta predominated community transmission. Concurrently, we constructed a test-negative control group by enrolling individuals between 13 April 2020 and 31 December 2022 with no evidence of SARS-CoV-2 infection. Participants in both groups were followed up for a median of 300 days. We estimated risks of new-incident cardiovascular, cerebrovascular, and other thrombotic complications using doubly robust competing-risks survival analysis. Risks were reported using 2 measures: hazard ratio (HR) and excess burden (EB) with 95% confidence intervals.
Results: We included 106 012 infected cases and 1 684 085 test-negative controls. Compared with the control group, individuals with COVID-19 exhibited increased risk (HR, 1.157 [1.069-1.252]) and excess burden (EB, 0.70 [.53-.88]) of new-incident cardiovascular and cerebrovascular complications. Risks decreased in a graded fashion for fully vaccinated (HR, 1.11 [1.02-1.22]) and boosted (HR, 1.10 [.92-1.32]) individuals. Conversely, risks and burdens of subsequent cardiovascular/cerebrovascular complications increased for hospitalized and severe COVID-19 cases (compared to nonhospitalized cases).
Conclusions: Increased risks and excess burdens of new-incident cardiovascular/cerebrovascular complications were reported among infected individuals; risks can be attenuated with vaccination and boosting.
Keywords: cardiovascular; cerebrovascular; complications; postacute sequelae of SARS-CoV-2 infection; thrombotic.